Mountain Hill Investment Partners Corp. Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC)

Mountain Hill Investment Partners Corp. acquired a new stake in shares of Bausch Health Companies Inc. (NYSE:BHC) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 7,000 shares of the company’s stock, valued at approximately $56,000.

A number of other hedge funds also recently made changes to their positions in the stock. Goldentree Asset Management LP raised its stake in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after acquiring an additional 6,958,717 shares during the period. Vanguard Group Inc. increased its stake in shares of Bausch Health Companies by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company’s stock worth $94,460,000 after purchasing an additional 145,078 shares in the last quarter. Bank of Montreal Can raised its position in shares of Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after purchasing an additional 2,685,675 shares during the period. SG Americas Securities LLC lifted its stake in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after buying an additional 1,263,706 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. bought a new position in Bausch Health Companies in the 3rd quarter worth $16,850,000. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Trading Up 0.5 %

Shares of BHC stock opened at $7.17 on Monday. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -59.70, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $11.46. The stock’s 50-day moving average price is $7.14 and its 200-day moving average price is $7.70.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. As a group, research analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BHC shares. Jefferies Financial Group reissued a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.